Cook Medical has obtained CE mark for PVA Foam Embolization Particles, designed for the treatment of symptomatic benign prostatic hyperplasia (BPH), also known as prostate enlargement.
BPH can lead to lower urinary tract symptoms and is expected to affect more than 50% of men by the time they reach 60 years of age, claims the company.
The company said BPH can now be treated with a minimally invasive alternative procedure Prostatic artery embolization (PAE).
The PAE procedure, which involves injecting the small particles into the blood vessels, blocks the blood which reduces the size of the prostate and relieves symptoms.
During the global patient trial, which the company claims is the largest trial to date, the PVA Foam Embolization Particles have shown positive short- and midterm results and provided durable relief of BPH symptoms.
Cook Medical peripheral intervention division vice president and global leader Rob Lyles said, "Consistent with this philosophy, we have worked hard to offer our PVA Foam Embolization particles for PAE as option for the millions of men suffering from symptoms of BPH."
